NVZMY
Novozymes A/S
OTC Markets OTCPKUSDEQUITY
Basic Materials
DELAYED
Buy
+20/100
Last price
64.97
▲ 1.00 (1.56%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
—
Prev close
63.97
Day high
65.26
Day low
64.79
Volume
3.50K
Market cap
$30.30B
P/E (TTM)
40.86
52W range
49.90 – 75.27
Trailing performance
Returnvs SPY
1W
+2.40%
+0.4%
1M
-4.54%
-5.7%
3M
+1.39%
-3.1%
6M
+5.85%
-12.3%
YTD
+2.12%
-12.1%
1Y
+5.92%
-10.5%
3Y
+61.58%
-20.7%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
5 more panels on NVZMY open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
0
Net selling
Buy transactions
0
0 shares
Sell transactions
0
—
Net transactions
0
Buys less sells
Sell : buy shares
—
Not enough filings
Insider-held shares
0
Total on file
Fundamentals
Market cap$30.30B
Enterprise value$33.12B
Revenue (TTM)$4.30B
Gross profit$2.42B
EBITDA$1.61B
Net income$631.60M
EPS (TTM)$1.59
Free cash flow$726.71M
Total cash$308.70M
Total debt$3.07B
Book value / share$26.88
Shares outstanding412.62M
Float347.62M
Short % of float—
Dividend yield1.56%
Beta (5Y)0.62
Valuation & profitability ratios
Trailing P/E40.86
Forward P/E24.39
PEG ratio1.99
Price / sales—
Price / book2.42
EV / revenue7.71
EV / EBITDA20.58
Gross margin56.39%
Operating margin23.44%
Profit margin14.70%
Return on equity5.77%
Return on assets3.79%
Debt / equity27.51
Current ratio1.74
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Total revenue | $4.16B | $3.83B | $2.40B | $2.36B | +8.5% |
| Operating revenue | $4.16B | $3.83B | $2.40B | $2.36B | +8.5% |
| Cost of revenue | $1.92B | $2.02B | $1.10B | $1.07B | -5.3% |
| Gross profit | $2.24B | $1.81B | $1.30B | $1.29B | +23.9% |
| Research & development | $463.80M | $413.20M | $270.70M | $268.56M | +12.2% |
| Selling, general & admin | $911.80M | $765.50M | $446.10M | $432.56M | +19.1% |
| Total operating expense | $1.36B | $1.15B | $693.90M | $691.06M | +18.1% |
| Operating income | $882.60M | $659.00M | $610.90M | $594.29M | +33.9% |
| Net interest income | -$59.60M | -$61.50M | -$20.00M | -$24.56M | +3.1% |
| Pre-tax income | $743.40M | $417.10M | $524.70M | $611.47M | +78.2% |
| Tax provision | $159.80M | $111.30M | $116.80M | $116.76M | +43.6% |
| Net income | $583.60M | $305.80M | $405.90M | $493.36M | +90.8% |
| Net income to common | $583.60M | $305.80M | $405.90M | $493.36M | +90.8% |
| Basic EPS | 1.25 | 0.67 | 1.47 | 1.78 | +86.6% |
| Diluted EPS | 1.25 | 0.67 | 1.46 | 1.77 | +86.6% |
| EBIT | $811.70M | $493.50M | $547.80M | $625.16M | +64.5% |
| EBITDA | $1.39B | $1.04B | $734.20M | $820.71M | +33.6% |
| Basic shares | 465.93M | 457.62M | 277.04M | 276.64M | +1.8% |
| Diluted shares | 467.56M | 459.60M | 277.87M | 278.73M | +1.7% |
| Line item | 2025 | 2024 | 2023 | 2022 | 2021 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $275.30M | $280.00M | $149.70M | $139.71M | — | -1.7% |
| Cash & short-term investments | $295.60M | $284.00M | $155.10M | $150.45M | — | +4.1% |
| Accounts receivable | $716.50M | $665.60M | $496.70M | $463.57M | — | +7.6% |
| Inventory | $772.20M | $720.60M | $486.70M | $510.41M | — | +7.2% |
| Total current assets | $1.98B | $1.88B | $1.27B | $1.24B | — | +5.5% |
| Property, plant & equipment | $3.00B | $2.97B | $1.65B | $1.62B | — | +1.0% |
| Goodwill & intangibles | $11.09B | $10.02B | $608.00M | $630.53M | — | +10.6% |
| Total assets | $16.35B | $15.20B | $3.81B | $3.76B | — | +7.6% |
| Total current liabilities | $2.74B | $1.09B | $972.70M | $934.52M | — | +151.9% |
| Current debt | — | $266.40M | $407.78M | $378.21M | $272.81M | — |
| Long-term debt | — | $1.53B | $581.32M | $485.71M | $494.40M | — |
| Total debt | — | $1.80B | $1.04B | $919.08M | $832.03M | — |
| Total liabilities | $5.49B | $4.02B | $1.88B | $1.85B | — | +36.7% |
| Retained earnings | $11.16B | $11.03B | $1.85B | $1.75B | — | +1.1% |
| Shareholder equity | $10.86B | $11.18B | $1.88B | $1.86B | — | -2.9% |
| Working capital | -$758.10M | $791.10M | $296.80M | $305.73M | — | -195.8% |
| Net tangible assets | -$233.20M | $1.15B | $1.27B | $1.23B | — | -120.2% |
| Shares issued | 468.30M | 468.30M | 281.00M | 281.00M | — | 0.0% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Net income | $583.60M | $305.80M | $407.90M | $494.70M | +90.8% |
| Depreciation & amortisation | $574.80M | $544.10M | $186.40M | $195.55M | +5.6% |
| Stock-based compensation | $20.40M | $28.80M | $20.30M | $17.04M | -29.2% |
| Change in working capital | $56.00M | $271.00M | -$22.30M | -$78.25M | -79.3% |
| Operating cash flow | $1.22B | $1.02B | $557.10M | $537.65M | +19.8% |
| Capital expenditure | -$470.80M | -$359.80M | -$275.80M | -$387.87M | -30.9% |
| Investing cash flow | -$1.97B | -$199.70M | -$286.20M | -$358.61M | -886.9% |
| Share buybacks | -$99.90M | $0 | $0 | -$67.11M | — |
| Dividends paid | -$402.70M | -$249.80M | -$383.20M | -$204.67M | -61.2% |
| Financing cash flow | $753.30M | -$703.20M | -$253.50M | -$167.76M | +207.1% |
| Free cash flow | $750.70M | $660.10M | $281.30M | $149.78M | +13.7% |
| End cash position | $275.30M | $280.00M | $149.70M | $139.71M | -1.7% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|
| Total revenue | $1.12B | $1.12B | $996.60M | $1.02B | $1.08B | -0.3% |
| Operating revenue | $1.12B | $1.12B | $996.60M | $1.02B | $1.08B | -0.3% |
| Cost of revenue | $494.50M | $484.60M | $437.80M | $474.00M | $483.30M | +2.0% |
| Gross profit | $621.70M | $634.70M | $558.80M | $544.50M | $594.30M | -2.0% |
| Research & development | $119.90M | $120.90M | $128.30M | $109.60M | $107.30M | -0.8% |
| Selling, general & admin | $244.60M | $244.90M | $249.70M | $220.20M | $212.30M | -0.1% |
| Total operating expense | $360.10M | $361.40M | $370.90M | $324.70M | $318.60M | -0.4% |
| Operating income | $261.60M | $273.30M | $187.90M | $219.80M | $275.70M | -4.3% |
| Net interest income | -$29.90M | -$8.60M | -$9.60M | -$15.70M | -$19.30M | -247.7% |
| Pre-tax income | $221.60M | $256.90M | $152.70M | $174.50M | $244.70M | -13.7% |
| Tax provision | $49.90M | $57.80M | $29.90M | $37.70M | $58.70M | -13.7% |
| Net income | $171.70M | $199.10M | $122.80M | $136.80M | $186.00M | -13.8% |
| Net income to common | $171.70M | $199.10M | $122.80M | $136.80M | $186.00M | -13.8% |
| Basic EPS | 0.37 | 0.43 | — | 0.29 | 0.40 | -14.0% |
| Diluted EPS | 0.37 | 0.43 | — | 0.29 | 0.40 | -14.0% |
| EBIT | $261.60M | $273.30M | $117.00M | $219.80M | $275.70M | -4.3% |
| EBITDA | $261.60M | $273.30M | $117.00M | $219.80M | $275.70M | -4.3% |
| Basic shares | 464.05M | 463.02M | — | 471.72M | 465.00M | +0.2% |
| Diluted shares | 467.30M | 467.20M | — | 471.72M | 468.10M | +0.0% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|---|
| Cash & equivalents | $308.70M | $327.20M | $275.30M | — | $328.20M | $249.50M | -5.7% |
| Cash & short-term investments | $313.60M | $329.40M | $295.60M | — | $365.40M | $256.50M | -4.8% |
| Accounts receivable | $792.10M | $756.40M | $716.50M | — | $704.40M | $741.60M | +4.7% |
| Inventory | $836.30M | $792.70M | $772.20M | — | $799.60M | $730.30M | +5.5% |
| Total current assets | $2.08B | $2.05B | $1.98B | — | $2.05B | $1.95B | +1.7% |
| Property, plant & equipment | $3.15B | $3.06B | $3.00B | — | $2.83B | $2.92B | +3.1% |
| Goodwill & intangibles | $11.12B | $11.14B | $11.09B | — | $11.21B | $9.88B | -0.2% |
| Total assets | $16.63B | $16.52B | $16.35B | — | $16.40B | $15.06B | +0.7% |
| Total current liabilities | $1.20B | $1.22B | $2.74B | — | $1.17B | $1.17B | -2.1% |
| Current debt | — | $289.10M | — | $303.00M | $347.00M | $429.90M | — |
| Long-term debt | $2.83B | $2.92B | — | $2.80B | $2.97B | $1.27B | -3.2% |
| Total debt | $3.07B | $3.21B | — | $3.11B | $3.32B | $1.70B | -4.5% |
| Total liabilities | $5.48B | $5.60B | $5.49B | — | $5.66B | $3.83B | -2.2% |
| Retained earnings | $11.03B | $11.09B | $11.16B | — | $11.04B | $11.20B | -0.6% |
| Shareholder equity | $11.15B | $10.92B | $10.86B | — | $10.74B | $11.23B | +2.2% |
| Working capital | $883.90M | $823.30M | -$758.10M | — | $880.80M | $775.70M | +7.4% |
| Net tangible assets | $35.40M | -$219.40M | -$233.20M | — | -$464.30M | $1.35B | +116.1% |
| Shares issued | 468.30M | 468.30M | 468.30M | 468.30M | 468.30M | — | 0.0% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|
| Net income | $171.70M | $199.10M | $122.80M | $136.80M | $186.00M | -13.8% |
| Change in working capital | -$34.60M | -$206.20M | $138.60M | $20.30M | -$260.80M | +83.2% |
| Operating cash flow | $356.20M | $167.10M | $328.20M | $320.10M | $106.40M | +113.2% |
| Capital expenditure | -$123.10M | -$93.10M | -$226.70M | -$82.20M | -$55.20M | -32.2% |
| Investing cash flow | -$174.10M | -$93.10M | -$226.20M | -$1.54B | -$38.30M | -87.0% |
| Share buybacks | $0 | $0 | $0 | -$69.10M | -$30.80M | — |
| Dividends paid | — | -$265.10M | $0 | -$262.40M | — | — |
| Financing cash flow | -$206.20M | -$25.90M | -$102.10M | $1.31B | -$102.10M | -696.1% |
| Free cash flow | $233.10M | $74.00M | $101.50M | $237.90M | $51.20M | +215.0% |
| End cash position | $308.70M | $327.20M | $275.30M | $328.20M | $249.50M | -5.7% |
Options analytics
Put / call volume
—
—
Put / call open interest
—
Positioning, not flow
Max pain
—
—
ATM implied vol
—
Nearest strike to spot
Skew (10% OTM)
—
—
Call volume
0
Contracts, this expiry
Put volume
0
Contracts, this expiry
Heaviest call OI
—
—
Heaviest put OI
—
—
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | — | — | $8.50B | +6.9% |
| Next quarter | — | — | $8.09B | +8.7% |
| Current year | 2.45 | 2 | $33.38B | +7.4% |
| Next year | 2.66 | 2 | $35.92B | +7.6% |
Analyst targets & ownership
Mean target$73.50
High target$83.00
Low target$64.00
Implied upside13.13%
Analyst count2
ConsensusBUY
Strong buy / Buy0 / 2
Hold1
Sell / Strong sell0 / 0
Held by insiders0.00%
Held by institutions5.37%
Institutions holding27
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
64.45
+0.81% from price
SMA 20
65.39
-0.64% from price
SMA 50
66.57
-2.41% from price
SMA 100
63.80
+1.84% from price
SMA 200
62.12
+4.58% from price
EMA 12
64.61
+0.55% from price
EMA 26
65.60
-0.97% from price
EMA 50
65.65
-1.03% from price
RSI (14)
47.0
Neutral
MACD (12,26,9)
-0.99
Hist -0.22
ATR (14)
1.43
2.21% of price
Realised vol 30D
23.0%
Annualised
Bollinger upper
68.46
20, 2σ
Bollinger lower
62.33
20, 2σ
50 / 200 cross
Golden
66.57 vs 62.12
Trend bias
Above 200
+4.58%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
0.11
Less volatile than market
Correlation to SPY
0.05
Largely independent
Realised vol 30D
23.0%
Annualised
Market vol 1Y
13.0%
SPY, annualised
Max drawdown 1Y
-20.0%
Peak to trough
Max drawdown 5Y
-53.4%
Peak to trough
ATR 14
1.43
2.21% of price
Beta (reported)
0.62
5Y monthly, from filing
Rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Aug 7, 15 | Jefferies | MAINTAINED | — | Hold |
Dividends & splits
Forward rate$1.02 / yr
Forward yield1.56%
5-year avg yield1.41%
Payout ratio64.89%
Ex-dividend dateAug 31, 2026
Next pay dateSep 16, 2026
Last split5:1
Split dateDec 9, 2011
Headlines
Transactions under Novonesis’ share buyback program
GlobeNewswire · 2d ago
Novonesis completes acquisition of MicroBioGen, strengthening its yeast capabilities
GlobeNewswire · 6d ago
Novonesis celebrates major expansion of West Allis production facility, strengthening North American dairy innovation and manufacturing
GlobeNewswire · 9d ago
Transactions under Novonesis’ share buyback program
GlobeNewswire · 9d ago
Transactions under Novonesis’ share buyback program
GlobeNewswire · 16d ago
Novozymes (CPSE:NSIS B) Could Be 13% Undervalued After €600 Million Patalganga Expansion
Simply Wall St. · 23d ago
Initiation of Novonesis’ share buyback program
GlobeNewswire · 23d ago
Novonesis to build next generation enzyme production facility in India
GlobeNewswire · 35d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.